×
About 26,934 results

Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
https://clinicaltrials.gov/ct2/show/NCT00715234

Jun 24th, 2013 - Although patient reminder/recall systems have been shown to be effective at improving vaccination coverage levels for infants and younger children, little is known about the effectiveness of such systems for increasing immunization rates in adolescent populations. The process of reminder/recall in adolescents, and vaccination of adolescents overall, presents particular challenges. Adolescents a...

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00019539

Jun 19th, 2013 - OBJECTIVES: I. Determine the effect of monoclonal antibody VEGF on time to progression, angiogenesis, and overall survival in patients with unresectable advanced renal cell cancer. II. Evaluate serum antibody levels and biologically active vascular endothelial growth factor levels in the plasma of patients treated with this regimen. III. Evaluate the toxicity of this regimen in these patients. ...

Photodynamic Therapy in Treating Patients With Skin Cancer
https://clinicaltrials.gov/ct2/show/NCT00002963

Jan 30th, 2013 - OBJECTIVES: Characterize the penetration of topically applied aminolevulinic acid (ALA) into the lesions of patients with primary basal cell and squamous cell carcinomas. Quantitate the depth of fluorescence achievable with varying application periods of ALA in these patients. Compare the results of tissue fluorescence with surface fluorescence measurements in these patients. OUTLINE: This is a...

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT00098527

Jul 1st, 2013 - PRIMARY OBJECTIVES: I. Determine the radiographic response rate (complete response and partial response) in patients with refractory adenocarcinoma of the stomach or gastroesophageal junction treated with FR901228 (depsipeptide). SECONDARY OBJECTIVES: I. Determine the median time to progression and progression-free survival of patients treated with this drug. II. Determine the grade 3 and 4 tox...

Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (...
https://clinicaltrials.gov/ct2/show/NCT03222076

Jul 30th, 2018 - Objectives: Primary Objective: 1. To evaluate the safety and tolerability of therapy with nivolumab alone or nivolumab + ipilimumab in resectable HCC in the context of presurgical therapy; to evaluate the safety and tolerability of therapy with nivolumab + ipilimumab in potentially resectable HCC in the context of pre-biopsy therapy. Secondary Objectives: To assess the efficacy of presurgical n...

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
https://clinicaltrials.gov/ct2/show/NCT00002819

Apr 10th, 2013 - OBJECTIVES: I. Compare progression-free and overall survival of patients with drug-sensitive, low-volume ovarian cancer that is persistent following standard therapy treated with salvage therapy comprising standard-dose paclitaxel and carboplatin vs high-dose carboplatin, mitoxantrone, and cyclophosphamide followed by bone marrow reconstitution. II. Compare the toxic effects of these two salvag...

PIPAC for Peritoneal Metastases of Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT03246321

Aug 10th, 2017 - Summary intended for the lay public Background of study: approximately a quarter of the patients who are diagnosed with colorectal cancer and metastases have their metastases in the peritoneum, the so called peritoneal metastases. The vast majority of these patients cannot be cured by surgery, frequently due to too many peritoneal metastases. These incurable patients have a very short life expe...

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
https://clinicaltrials.gov/ct2/show/NCT00107432

Jun 4th, 2013 - PRIMARY OBJECTIVES: I. To determine the response rate (partial response (PR) and complete response (CR)) in patients with malignant mesothelioma treated with BAY 43-9006. SECONDARY OBJECTIVES: I. To determine 3-month failure free survival in patients with malignant mesothelioma treated with BAY 43-9006. II. To describe the median and overall survival of malignant mesothelioma patients treated w...

Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
https://clinicaltrials.gov/ct2/show/NCT00003775

Sep 12th, 2012 - OBJECTIVES: I. Determine the median time to progression, median survival, and objective response of patients with anaplastic astrocytoma or anaplastic oligoastrocytoma in first relapse treated with intravenous leflunomide (SU101). II. Assess the safety of SU101 in these patients. III. Describe the health-related quality of life of patients treated with intravenous SU101. OUTLINE: This is an ope...

IM-862 in Treating Patients With Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT00003773

May 21st, 2014 - OBJECTIVES: I. Determine the maximum tolerated dose of IM-862 administered intranasally in patients with recurrent ovarian cancer. II. Determine the toxicity of this regimen in this patient population. III. Obtain preliminary data regarding the efficacy of this drug in these patients. IV. Evaluate the effect of this drug in serum levels of vascular endothelial growth factor and transforming gro...

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00003175

Dec 3rd, 2013 - OBJECTIVES: I. Determine the response rate and toxic effects of continuous fluorouracil in patients with recurrent locally advanced or metastatic transitional cell urinary tract carcinoma. II. Determine the feasibility of this treatment in this patient population. OUTLINE: Patients receive continuous intravenous fluorouracil by a Baxter Infusor for 24 weeks. Patients are evaluated for complete ...

The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
https://clinicaltrials.gov/ct2/show/NCT03240835

Jun 11th, 2018 - The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma patients with chemoradiotherapy.

Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
https://clinicaltrials.gov/ct2/show/NCT00002932

Nov 20th, 2014 - OBJECTIVES: I. Determine the percentage of patients for whom a complete course of therapy can be administered using targeted supradose cisplatin chemoradiation in patients with squamous cell carcinoma of the head and neck. II. Determine the partial and complete response rate of cisplatin chemoradiation. III. Determine the incidence of adverse events using cisplatin chemoradiation therapy. IV. D...

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors
https://clinicaltrials.gov/ct2/show/NCT00002619

Nov 8th, 2012 - OBJECTIVES: I. Estimate the overall survival, progression-free interval, and time to progression or recurrence in patients with nondisseminated glioblastoma multiforme or diffuse intrinsic brain stem tumors that are nonprogressive following surgery (if feasible) and involved-field irradiation and treated with intensive chemotherapy followed by autologous peripheral blood stem cell (PBSC) or aut...

Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT00006353

Sep 23rd, 2012 - OBJECTIVES: I. Compare the efficacy of radiotherapy with or without temozolomide in terms of overall survival in patients with newly diagnosed glioblastoma multiforme. II. Compare the toxicity profiles of these regimens in these patients. III. Compare the progression free survival of these patients treated with these regimens. IV. Compare the quality of life in these patients treated with these...

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00018941

Jun 16th, 2013 - OBJECTIVES: I. Determine the response rate and overall survival of patients with metastatic renal cell carcinoma treated with either low-dose or high-dose intravenous interleukin-2 (IL-2) or subcutaneous IL-2. II. Compare the toxic effects of these 3 regimens in this patient population. OUTLINE: This is a randomized study. Patients are stratified according to presence of renal tumor (yes vs no)...

Combination Chemotherapy in Treating Patients With Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00014534

Jul 13th, 2016 - OBJECTIVES: Primary Compare the survival of patients with completely resected locally advanced transitional cell carcinoma of the bladder treated with adjuvant doxorubicin and gemcitabine followed by paclitaxel and cisplatin vs adjuvant cisplatin and gemcitabine. Secondary Compare the toxicity profiles of these regimens in these patients. OUTLINE: This is a randomized study. Patients are strati...

Airway Inflammatory Profile Among Cleaning Workers From Different Workplaces
https://clinicaltrials.gov/ct2/show/NCT03311048

Mar 29th, 2018 - Were recruited to participate in the study individuals from four different workplaces: Hospital; University; Housekeeper and Control (office workers). The research was performed in Cacoal city, Rondonia, Brazil. Smokers (active), pregnant, lactating, and individuals at continuing therapy for treating disorders of the airways were excluded. Clinical profile and respiratory symptoms employees eva...

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT00381797

Nov 27th, 2017 - PRIMARY OBJECTIVES: I. Estimate the rates of objective response observed prior to disease progression during the first four courses of treatment with bevacizumab and irinotecan hydrochloride in pediatric patients with recurrent, progressive, or refractory malignant glioma (Stratum A [closed to accrual as of 4/21/2009]) or recurrent/progressive/refractory intrinsic brain stem glioma (Stratum B [...

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00393796

Nov 12th, 2014 - This study is a randomized, blinded, placebo-controlled study evaluating the drug, SUO11248 (SUTENT), for maintenance therapy in advanced urothelial cancer.